Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 8/20 | 0.63 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ERG | P11308 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9931835 | 0.89 | SMO (0.61) | SMODRD4GRM2MEN1KMT2A | |
| SCHEMBL1533944 | 0.88 | SMO (0.48) | SMODRD4GRM2MEN1KMT2A | |
| SCHEMBL9932074 | 0.88 | SMO (0.48) | SMODRD4GRM2MEN1KMT2A | |
| SCHEMBL9968426 | 0.86 | SMO (0.48) | SMODRD4GRM2MEN1KMT2A | |
| SCHEMBL9932442 | 0.86 | SMO (0.48) | SMODRD4GRM2MEN1KMT2A | |
| SCHEMBL9968425 | 0.85 | SMO (0.47) | SMODRD4GRM2MEN1KMT2A | |
| SCHEMBL9932487 | 0.85 | SMO (0.47) | SMODRD4GRM2MEN1KMT2A | |
| SCHEMBL9932722 | 0.84 | PIK3CA (0.48) | SMODRD4GRM2MEN1KMT2A | |
| SCHEMBL9968424 | 0.82 | GRM2 (0.47) | SMODRD4GRM2MEN1KMT2A | |
| SCHEMBL9932077 | 0.82 | SMO (0.47) | SMODRD4GRM2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011027249-A2 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | SMO, RB1, GLI1 | SMO 1/4885DRD4 2786/4885GRM2 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.